Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
The vaccine is under FDA review
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Subscribe To Our Newsletter & Stay Updated
